Prolonged oral morphine therapy for severe angina pectoris

Meir Mouallem*, Eli Schwartz, Zvi Farfel

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

3 Scopus citations


Patients with intractable angina pectoris despite optimal drug therapy, who are not candidates for revascularization procedures, pose a very difficult problem. We evaluated the role of chronic opioid therapy in four such patients. The patients (mean age 79.5 years) were treated by low doses (mean 40 mg/day) of controlled-release oral morphine (CRM) for 1 to 5 years. The treatment was followed by a marked decline in the rate of admissions and hospitalization periods. The number of admissions decreased from a mean of 6 during the year prior to CRM therapy to 1.5 the following year. The duration of hospitalization for angina pectoris during these periods decreased from a mean of 42 ± 35 days to 6 ± 10 days (p < 0.05). Side effects were negligible and consisted mainly of lactulose-responsive constipation. We suggest that prolonged oral morphine therapy may be administered with good efficacy and no significant side effects in selected patients with intractable angina pectoris. (C) U.S. Cancer Pain Relief Committee 2000.

Original languageEnglish
Pages (from-to)393-397
Number of pages5
JournalJournal of Pain and Symptom Management
Issue number5
StatePublished - May 2000
Externally publishedYes


  • Intractable angina pectoris
  • Oral morphine


Dive into the research topics of 'Prolonged oral morphine therapy for severe angina pectoris'. Together they form a unique fingerprint.

Cite this